Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes
Authors' conclusion
IDegLira was associated with significantly greater increases in dTIR versus basal insulin alone in people with T2D.
Study context
- Population
- People with T2D in the DUAL V and DUAL VIII trials
- Comparison
- IDegLira vs glargine U100
- Primary endpoint
- Change from baseline to end of trial in derived time in range (dTIR; % of nine-point SMBG readings within 70-180 mg/dL)
- Follow-up
- EOT: 26 weeks (DUAL V) and 104 weeks (DUAL VIII)
Primary result
As reported in the abstract
Change from baseline to EOT in dTIR
ETD (DUAL V)
4.18 %
P = 0.027
IDegLira
ETD (DUAL VIII)
5.17 %
P = 0.001
IDegLira
Further findings
Achieving ≥70% dTIR at EOT, DUAL V · 26 weeks
P = 0.7541
Achieving ≥70% dTIR at EOT, DUAL VIII · 104 weeks
P < 0.0001
≥5% increase in dTIR from baseline to EOT, DUAL V · 26 weeks
P = 0.9043
≥5% increase in dTIR from baseline to EOT, DUAL VIII · 104 weeks
P < 0.0001
Original publication
Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes. J Diabetes Sci Technol. Published 29 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →